United Therapeutics buys Thymmune Therapeutics
Seeking Alpha ·
United Therapeutics ( UTHR ) said it acquired privately held preclinical biotech Thymmune Therapeutics for $140M in cash, with potential earn-out payments of up to $160M tied to clinical and regulatory milestones through the end of 2031. The acquisition adds Thymmune's regenerative
DYAX Investor Sentiment
Bullish (Long) 53% · Bearish (Short) 47%
315 participants
Related News
- AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC
- The average investor is running away from 'Magnificent 7' stocks
- Tesla Deliveries Due With EV Giant's Stock Near Buy Point (Live Coverage)
- With the SpaceX IPO Reshaping the Nasdaq, Is QQQ Still a Smart Investment Right Now?
- SK Hynix removing price caps on long-term supply agreements: report
- Dollar Tree restores share buyback authorization to $2.5B